BiomX Inc. (PHGE) Income Statement
PHGE 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsPHGE revenue and net income
PHGE growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
PHGE quarterly EPS vs estimates
BiomX beat the analyst EPS estimate in 4 of the last 6 quarters.
PHGE income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $2.9M | $1.8M | $871,000 | $2.5M | $2.6M | $2.2M | $318,000 | $210,000 | — | $95,000 |
| Gross profit | −$2.9M | −$1.8M | −$871,000 | −$2.7M | −$2.6M | −$2.2M | −$405,000 | −$210,000 | — | −$95,000 |
| Research & development | $23.3M | $24.7M | $19.0M | $16.2M | $22.7M | $21.6M | $14.0M | $9.6M | — | $4.7M |
| Sales, general & admin | $6.7M | $11.8M | $8.7M | $9.5M | $11.3M | $9.1M | $8.2M | $3.4M | — | $2.5M |
| Total operating expenses | $30.0M | $37.2M | $26.8M | $27.2M | $35.5M | $30.3M | $22.2M | $12.9M | — | $7.3M |
| Operating income | −$32.9M | −$39.0M | −$27.7M | −$27.2M | −$35.5M | −$30.3M | −$22.2M | −$13.1M | −$1,030 | −$7.4M |
| Interest income | $460,000 | $1.0M | $792,000 | $464,000 | $86,000 | $641,000 | $921,000 | $892,946 | — | — |
| Interest expense | $984,000 | $2.8M | $2.4M | $2.1M | $699,000 | $7,000 | $64,000 | $225,000 | $0 | $0 |
| Income before taxes | −$36.2M | −$17.7M | −$26.1M | −$28.3M | −$36.2M | −$30.1M | −$20.6M | −$12.7M | −$1,030 | −$6.4M |
| Income taxes | $7,000 | $13,000 | $23,000 | $65,000 | $67,000 | −$172,000 | −$1.6M | $225,000 | — | — |
| Net income | −$36.2M | −$17.7M | −$26.2M | −$28.3M | −$36.2M | −$30.1M | −$20.6M | −$12.7M | −$1,030 | −$6.4M |
| EBITDA | −$32.3M | −$13.1M | −$22.8M | −$23.7M | −$32.9M | −$28.1M | −$21.9M | −$12.5M | — | −$6.3M |
| EPS (diluted) | −$30.84 | −$29.26 | −$86.30 | −$142.70 | −$128.00 | −$247.00 | −$0.38 | $0.01 | −$0.01 | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $332,000 | $0 | $0 | $0 | $0 | $0 | $172,000 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $235,000 | — | $1.2M | $1.2M | $292,000 | $236,000 | −$2.6M | $322,000 | $331,000 | $229,000 | — | $219,000 |
| Gross profit | $97,000 | — | −$1.2M | −$1.2M | −$292,000 | −$236,000 | $2.7M | −$322,000 | −$331,000 | −$229,000 | — | −$219,000 |
| Research & development | $128,000 | $315,000 | $4.9M | $6.1M | $5.0M | $5.2M | $11.6M | $7.3M | $6.9M | $4.1M | $2.7M | $5.6M |
| Sales, general & admin | $5.4M | $1.6M | $2.3M | $2.4M | $2.4M | $2.5M | $1.5M | $3.2M | $2.8M | $2.7M | $2.6M | $2.2M |
| Total operating expenses | $5.5M | $1.3M | $6.0M | $7.3M | $7.1M | $7.8M | −$16.7M | $10.2M | $9.7M | $6.6M | $5.3M | $7.6M |
| Operating income | −$5.4M | −$1.3M | −$7.2M | −$8.5M | −$7.4M | −$7.8M | $16.7M | −$10.5M | −$9.7M | −$6.8M | −$5.3M | −$7.8M |
| Interest income | — | — | — | $84,000 | — | — | — | $332,000 | $329,000 | — | $88,000 | $382,000 |
| Interest expense | $25,000 | $569,000 | $223,000 | $5,000 | $30,000 | $810,000 | $5,000 | $5,000 | $13,000 | $2.6M | $520,000 | $574,000 |
| Income before taxes | −$3.8M | −$19.1M | −$13.3M | −$9.2M | −$6.0M | −$7.7M | −$14.5M | $9.6M | $4.5M | −$17.3M | −$5.5M | −$7.9M |
| Income taxes | — | — | $1,000 | $3,000 | $2,000 | $1,000 | $3,000 | −$19.3M | $5,000 | $5,000 | — | $8,000 |
| Net income | −$3.8M | −$19.1M | −$13.3M | −$9.2M | −$6.0M | −$7.7M | −$14.5M | $5.1M | $4.5M | −$17.3M | −$5.5M | −$7.9M |
| EBITDA | −$3.8M | −$565,500 | −$12.0M | −$7.9M | −$5.7M | −$7.4M | −$7.6M | $10.0M | $4.8M | −$14.5M | — | −$7.1M |
| EPS (diluted) | −$0.37 | −$7.38 | −$21.39 | −$5.51 | −$3.61 | −$0.33 | −$21.85 | $5.89 | $1.90 | −$15.20 | −$0.80 | −$24.70 |
| Gross margin | 29.2% | — | — | — | — | — | 1,598.3% | — | — | — | — | — |
| Operating margin | −1,630.7% | — | — | — | — | — | 9,700.6% | — | — | — | — | — |
| Net margin | −1,136.1% | — | — | — | — | — | −8,437.8% | — | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in PHGE's financial statements (latest annual report filed February 19, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
PHGE financial results
BiomX reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $36.2 million. Diluted earnings per share came to −$30.84.
See the PHGE stock overview for the latest quote and news, or the PHGE chart for price history and technical indicators.
PHGE income statement FAQ
Does BiomX have revenue?
BiomX reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is BiomX profitable?
No. BiomX reported a net loss of $36.2 million in fiscal 2025.
How much does BiomX spend on research and development?
BiomX spent $23.3 million on research and development in fiscal 2025.
What are BiomX's earnings per share?
BiomX earned $-30.84 per diluted share in fiscal 2025, compared with $-29.26 a year earlier.
When does BiomX's fiscal year end?
BiomX's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 19, 2026.